Drugs / LM-24C5
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06187402 | Dec 2023 → Jun 2026 overdue | neoplasm | LaNova Medicines Limited | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07387081 | Dec 2025 → May 2028 expected | — | LaNova Medicines Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM-24C5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07387081 ↗ |
| Route | Intravenous | “Administered intravenously” NCT06187402 ↗ |